Pralsetinib
Pralsetinib is a targeted therapy medication known as a RET inhibitor used to treat certain cancers driven by RET gene alterations. It is prescribed for adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. As a precision medicine, it specifically targets cancer cells with RET abnormalities while sparing many healthy cells.
Pralsetinib is a RET kinase inhibitor used to treat RET-altered thyroid cancers and lung cancer.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- L01EX23
- RxNorm
- 2394936
- Generic
- Pralsetinib
- Class
- atc-l01
- Brands
- Gavreto
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- capsule
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Pralsetinib is indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced or metastatic RET-mutant medullary thyroid cancer (MTC), and RET fusion-positive thyroid cancer requiring systemic therapy.
Pralsetinib is a selective RET (rearranged during transfection) kinase inhibitor that blocks abnormal RET proteins produced by RET gene fusions and mutations. By inhibiting RET signaling, it prevents cancer cell growth and proliferation.
Common side effects may include fatigue, constipation, musculoskeletal pain, and elevated blood pressure. Pralsetinib may cause serious adverse events including pneumonitis, hepatotoxicity, and cardiac dysfunction. Patients should have RET status confirmed by an FDA-approved test before starting treatment. Drug interactions with strong CYP3A inhibitors or inducers should be carefully managed.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy